ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Targeted therapy with the selective inhibitors of BCR-ABL tyrosine kinase activity has dramatically changed the treatment of chronic myeloid leukemia (CML) in the last 20 years (1).